2-[1-(pyrrol-2-yl)ethylidene] hydrazinecarbothioamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 2-[1-(pyrrol-2-yl)ethylidene] hydrazinecarbothioamide
• 英文别名: (E)-2-(1-(1H-pyrrol-2-yl)ethylidene)hydrazinecarbothioamide；1-pyrrol-2-yl-ethanone thiosemicarbazone；1-Pyrrol-2-yl-aethanon-thiosemicarbazon；Hydrazinecarbothioamide, 2-[1-(1H-pyrrol-2-yl)ethylidene]-；[(E)-1-(1H-pyrrol-2-yl)ethylideneamino]thiourea
• 化学式: C₇H₁₀N₄S
• 分子量: 182.249
• InChiKey: YYZCEOGYVYXDPC-BJMVGYQFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  98.3
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  bis-triphenylphosphine-palladium(II) chloride 、 2-[1-(pyrrol-2-yl)ethylidene] hydrazinecarbothioamide 在 三乙胺 作用下， 以 甲醇 为溶剂， 以84 %的产率得到
  参考文献：
  名称：

  钯螯合物的合成和结构表征：苯并噻唑的可持续合成

  摘要：

  已经描述了一种有效的 Pd(II)N^N^S 钳型催化剂促进从伯醇和 2-氨基苯硫酚通过无受体脱氢偶联 (ADC) 方法可持续构建药学上重要的苯并噻唑衍生物。除了 L 1和 L 3之外，新合成的配体 L 2和 Pd(II)配合物通过分析和傅立叶变换红外光谱 (FT-IR)、紫外-可见 (UV-vis) 和核磁共振 ( NMR）光谱技术。此外，配合物2和3的 ORTEP 视图由单晶 XRD 研究建立，证明了缩氨基硫脲配体的配位，并揭示了 Pd(II) 离子周围的方形平面几何结构。目前的均相催化系统涉及通过 C-S 和 C-N 键的形成合成一系列苯并噻唑，收率高达 93%。所描述的方法采用可持续、丰富且廉价的醇作为起始材料，使用 1 mol% 催化剂负载，水和氢气是唯一的副产品。此外，还提出了一种可能的机制，涉及通过伯醇脱氢原位形成醛。2-(4-甲氧基苯基) 苯并 [d] 噻唑的大规模合成说明了本催化方案的合成效用。

  DOI：

  10.1002/aoc.7062
• 作为产物：
  描述：

  2-乙酰基吡咯 、 氨基硫脲 生成 2-[1-(pyrrol-2-yl)ethylidene] hydrazinecarbothioamide
  参考文献：
  名称：

  The Chemotherapy of Tuberculosis. III. Thiosemicarbazide Derivatives

  摘要：

  DOI：

  10.1021/ja01128a509

文献信息

• Thiadiazoline derivative
  申请人：Murakata Chikara

  公开号：US20060074113A1

  公开（公告）日：2006-04-06

  (wherein R 1 and R 4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R 5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R 2 represents —C(═W)R 6 or the like; R 3 represents a hydrogen atom, —C(═W A )R 6A , or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.

  提供了一种抗肿瘤剂，其中R1和R4相同或不同，每个代表氢原子，取代或未取代的低级烷基，取代或未取代的低级炔基，取代或未取代的低级烯基或类似物；R5代表取代或未取代的杂环基，取代或未取代的芳基或类似物；R2代表-C（═W）R6或类似物；R3代表氢原子，-C（═WA）R6A或类似物。该抗肿瘤剂包含由上述通式（I）表示的噻二唑啉衍生物或其药理学上可接受的盐作为活性成分。
• THIADIAZOLINE DERIVATIVE
  申请人：MURAKATA Chikara

  公开号：US20080207706A1

  公开（公告）日：2008-08-28

  (wherein R 1 and R 4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R 5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R 2 represents —C(═W)R 6 or the like; R 3 represents a hydrogen atom, —C(═W A )R 6A , or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.

  提供了一种抗肿瘤剂，其包括由上述一般式（I）表示的噻二唑啉衍生物或其药学上可接受的盐作为活性成分，其中R1和R4相同或不同，每个代表氢原子，取代或未取代的低碳基，取代或未取代的低炔基，取代或未取代的低烯基或类似物; R5代表取代或未取代的杂环基，取代或未取代的芳基或类似物; R2代表-C（═W）R6或类似物; R3代表氢原子，-C（═WA）R6A或类似物。
• Mitotic kinesin inhibitor
  申请人：Murakata Chikara

  公开号：US20070155804A1

  公开（公告）日：2007-07-05

  A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R 1 represents a hydrogen atom and the like, R 2 represents a hydrogen atom, —C(═W)R 6 (wherein W represents an oxygen atom or a sulfur atom, and R 6 represents substituted or unsubstituted lower alkyl and the like) and the like, R 3 represents —C(═Z)R 19 (wherein Z represents an oxygen atom or a sulfur atom, and R 19 represents substituted or unsubstituted lower alkyl and the like) and the like, R 4 represents substituted or unsubstituted lower alkyl and the like, and R 5 represents substituted or unsubstituted aryl and the like] and the like are provided.

  一种有丝分裂动力蛋白Eg5抑制剂，其包括由通式（I）表示的噻二唑衍生物或其药学上可接受的盐作为活性成分：[其中R1代表氢原子等，R2代表氢原子，-C（═W）R6（其中W代表氧原子或硫原子，R6代表取代或未取代的低级烷基等）等，R3代表-C（═Z）R19（其中Z代表氧原子或硫原子，R19代表取代或未取代的低级烷基等）等，R4代表取代或未取代的低级烷基等，R5代表取代或未取代的芳基等]等。
• Mitotic Kinesin Inhibitor
  申请人：KATO Kazuhiko

  公开号：US20110275827A1

  公开（公告）日：2011-11-10

  A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R 1 represents a hydrogen atom and the like, R 2 represents a hydrogen atom, —C(═W)R 6 (wherein W represents an oxygen atom or a sulfur atom, and R 6 represents substituted or unsubstituted lower alkyl and the like) and the like, R 3 represents —C(═Z)R 19 (wherein Z represents an oxygen atom or a sulfur atom, and R 19 represents substituted or unsubstituted lower alkyl and the like) and the like, R 4 represents substituted or unsubstituted lower alkyl and the like, and R 5 represents substituted or unsubstituted aryl and the like] and the like are provided.

  一种有丝分裂动力蛋白Eg5抑制剂，该抑制剂包括由通式（I）所表示的噻二唑衍生物或其药学上可接受的盐作为活性成分：[其中R1表示氢原子等，R2表示氢原子，-C（═W）R6（其中W表示氧原子或硫原子，R6表示取代或未取代的低碳基等）等，R3表示-C（═Z）R19（其中Z表示氧原子或硫原子，R19表示取代或未取代的低碳基等）等，R4表示取代或未取代的低碳基等，R5表示取代或未取代的芳基等]等。
• M-STAGE KINESIN INHIBITOR
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1616866A1

  公开（公告）日：2006-01-18

  A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom, -C(=W)R6 (wherein W represents an oxygen atom or a sulfur atom, and R6 represents substituted or unsubstituted lower alkyl and the like) and the like, R3 represents -C(=Z)R19 (wherein Z represents an oxygen atom or a sulfur atom, and R19 represents substituted or unsubstituted lower alkyl and the like) and the like, R4 represents substituted or unsubstituted lower alkyl and the like, and R5 represents substituted or unsubstituted aryl and the like] and the like are provided.

  一种有丝分裂驱动蛋白 Eg5 抑制剂，其活性成分包括通式 (I) 所代表的噻二唑 啉衍生物或其药理学上可接受的盐： [其中 R1 代表氢原子等，R2 代表氢原子、-C(＝W)R6（其中 W 代表氧原子或硫原子，R6 代表取代或未取代的低级烷基等）等，R3 代表-C(＝Z)R19（其中 Z 代表氧原子或硫原子、R4代表取代或未取代的低级烷基等，R5代表取代或未取代的芳基等]等。